BE2012C020I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2012C020I2 BE2012C020I2 BE2012C020C BE2012C020C BE2012C020I2 BE 2012C020 I2 BE2012C020 I2 BE 2012C020I2 BE 2012C020 C BE2012C020 C BE 2012C020C BE 2012C020 C BE2012C020 C BE 2012C020C BE 2012C020 I2 BE2012C020 I2 BE 2012C020I2
- Authority
- BE
- Belgium
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/12—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to hydrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01203090 | 2001-08-13 | ||
EP02077748 | 2002-06-10 | ||
EP02764839A EP1419152B1 (en) | 2001-08-13 | 2002-08-09 | Hiv inhibiting pyrimidines derivatives |
PCT/EP2002/008953 WO2003016306A1 (en) | 2001-08-13 | 2002-08-09 | Hiv inhibiting pyrimidines derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
BE2012C020I2 true BE2012C020I2 (en) | 2021-07-19 |
Family
ID=26076978
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE2012C020C BE2012C020I2 (en) | 2001-08-13 | 2012-05-08 | |
BE2012C022C BE2012C022I2 (en) | 2001-08-13 | 2012-05-24 | |
BE2022C531C BE2022C531I2 (en) | 2001-08-13 | 2022-07-28 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE2012C022C BE2012C022I2 (en) | 2001-08-13 | 2012-05-24 | |
BE2022C531C BE2022C531I2 (en) | 2001-08-13 | 2022-07-28 |
Country Status (38)
Country | Link |
---|---|
US (8) | US7125879B2 (en) |
EP (3) | EP1419152B1 (en) |
JP (4) | JP2005507380A (en) |
KR (2) | KR100969273B1 (en) |
CN (2) | CN101816658B (en) |
AP (1) | AP1610A (en) |
AR (1) | AR036387A1 (en) |
AT (1) | ATE517891T1 (en) |
AU (1) | AU2002329238C1 (en) |
BE (3) | BE2012C020I2 (en) |
BR (3) | BRPI0211909B8 (en) |
CA (1) | CA2452217C (en) |
CY (3) | CY1112331T1 (en) |
DE (1) | DE122012000038I1 (en) |
DK (2) | DK3808743T3 (en) |
EA (1) | EA006656B1 (en) |
EG (1) | EG24684A (en) |
ES (3) | ES2799408T3 (en) |
FR (3) | FR12C0035I2 (en) |
HK (2) | HK1070066A1 (en) |
HR (3) | HRP20192051B1 (en) |
HU (5) | HU230192B1 (en) |
IL (2) | IL160328A0 (en) |
JO (1) | JO3429B1 (en) |
LT (2) | LT3808743T (en) |
LU (2) | LU92001I2 (en) |
MX (1) | MXPA04001401A (en) |
MY (1) | MY189572A (en) |
NO (3) | NO327639B1 (en) |
NZ (1) | NZ530951A (en) |
OA (1) | OA12652A (en) |
PA (1) | PA8552901A1 (en) |
PL (2) | PL216398B1 (en) |
PT (1) | PT1419152E (en) |
SI (2) | SI3808743T1 (en) |
UA (1) | UA78221C2 (en) |
WO (1) | WO2003016306A1 (en) |
ZA (1) | ZA200401159B (en) |
Families Citing this family (149)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7638522B2 (en) * | 2001-08-13 | 2009-12-29 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile |
MY169670A (en) * | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
JO3429B1 (en) * | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | Hiv inhibiting pyrimidines derivatives |
US8101629B2 (en) | 2001-08-13 | 2012-01-24 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
EA007272B1 (en) | 2002-03-13 | 2006-08-25 | Янссен Фармацевтика Н. В. | New inhibitors of histone deacetylase |
AR039540A1 (en) | 2002-05-13 | 2005-02-23 | Tibotec Pharm Ltd | MICROBICIDE COMPOUNDS WITH PIRIMIDINE OR TRIAZINE CONTENT |
MXPA05001096A (en) | 2002-07-29 | 2005-11-23 | Rigel Pharmaceuticals Inc | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds. |
CN102702111B (en) | 2002-08-09 | 2014-12-17 | 詹森药业有限公司 | Processes for the preparation of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile |
CN1717396A (en) * | 2002-11-28 | 2006-01-04 | 舍林股份公司 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents |
MXPA05008364A (en) * | 2003-02-07 | 2005-11-04 | Janssen Pharmaceutica Nv | Pyrimidine derivatives for the prevention of hiv infection. |
EP1597242B1 (en) * | 2003-02-07 | 2008-07-23 | Janssen Pharmaceutica N.V. | Hiv inhibiting 1,2,4-triazines |
CL2004000306A1 (en) | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | COMPOUNDS DERIVED FROM PYRIMIDINE REPLACED WITH INDANO; PROCESS FOR PREPARATION; PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT; PHARMACEUTICAL COMBINATION; AND ITS USE FOR THE TREATMENT OR PROFILAXIS OF AN INFECTIOUS DISEASE. |
BRPI0412734A (en) | 2003-07-17 | 2006-09-26 | Tibotec Pharm Ltd | process for preparing particles containing an antiviral |
US8178671B2 (en) | 2003-07-30 | 2012-05-15 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds |
SI1660458T1 (en) * | 2003-08-15 | 2012-05-31 | Novartis Ag | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
TWI365744B (en) * | 2003-09-03 | 2012-06-11 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
EP1668011B1 (en) * | 2003-09-25 | 2011-03-02 | Janssen Pharmaceutica NV | Hiv replication inhibiting purine derivatives |
SG156687A1 (en) | 2004-07-28 | 2009-11-26 | Janssen Pharmaceutica Nv | Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
CN101035773B (en) | 2004-08-10 | 2012-06-06 | 詹森药业有限公司 | HIV inhibiting 1.2.4-triazin-6-one derivates |
MX2007002236A (en) | 2004-08-25 | 2007-07-09 | Ardea Biosciences Inc | S-triazolyl -mercaptoacetanildes as inhibitors of hiv reverse transcriptase. |
WO2007050087A1 (en) | 2004-08-25 | 2007-05-03 | Ardea Biosciences, Inc. | N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS |
BRPI0514861A (en) * | 2004-09-02 | 2008-06-24 | Janssen Pharmaceutica Nv | 4 - ((4 - ((4- (2-cyanoethenyl) -2,6-dimethylphenyl) amino) -2-pyrimidinyl) amino) benzonitrile furamate |
CN101068597B (en) * | 2004-09-02 | 2012-04-18 | 詹森药业有限公司 | Fumarate of 4-((4-(4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile |
KR101284361B1 (en) * | 2004-09-02 | 2013-07-15 | 얀센 파마슈티카 엔.브이. | Hydrochloride of 4-((4-(4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile |
EP1789139B1 (en) * | 2004-09-02 | 2012-03-21 | Janssen Pharmaceutica NV | Fumarate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl amino -2-pyrimidinyl amino benzonitrile |
JP4912309B2 (en) * | 2004-09-02 | 2012-04-11 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Hydrochloride of 4-[[4-[[4- (2-Cyanoethenyl) -2,6-dimethylphenyl] amino] -2-pyrimidinyl] amino] benzonitrile |
JP5043668B2 (en) | 2004-09-20 | 2012-10-10 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | Heterocyclic derivatives and their use as therapeutic agents |
BRPI0515500A (en) | 2004-09-20 | 2008-07-29 | Xenon Pharmaceuticals Inc | pyridazine derivatives for stearoyl coa desaturase inhibition |
BRPI0515489A (en) | 2004-09-20 | 2008-07-29 | Xenon Pharmaceuticals Inc | heterocyclic derivatives and their use as stearoyl coat desaturase inhibitors |
AU2005329423A1 (en) | 2004-09-20 | 2006-09-28 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
AR051092A1 (en) | 2004-09-20 | 2006-12-20 | Xenon Pharmaceuticals Inc | HETEROCICLIC DERIVATIVES AND THEIR USE AS INHIBITORS OF ESTEAROIL-COA |
EP1799668A1 (en) | 2004-09-20 | 2007-06-27 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase |
US7919496B2 (en) | 2004-09-20 | 2011-04-05 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes |
MX2007003796A (en) | 2004-09-30 | 2007-04-25 | Tibotec Pharm Ltd | Hiv inhibiting 5-substituted pyrimidines. |
CA2577467C (en) | 2004-09-30 | 2013-05-28 | Tibotec Pharmaceuticals Ltd. | Hiv inhibiting 5-heterocyclyl pyrimidines |
RU2403244C2 (en) * | 2004-09-30 | 2010-11-10 | Тиботек Фармасьютикалз Лтд. | Hiv-inhibiting 5-carbo- or heterocyclic substituted pyrimidines |
WO2006068770A1 (en) | 2004-11-24 | 2006-06-29 | Rigel Pharmaceuticals, Inc. | Spiro-2, 4-pyrimidinediamine compounds and their uses |
DE602006010979D1 (en) | 2005-01-19 | 2010-01-21 | Rigel Pharmaceuticals Inc | PRODRUGS FROM 2,4-PYRIMIDIN DIAMIN COMPOUNDS AND THEIR USES |
ES2548729T3 (en) | 2005-03-31 | 2015-10-20 | Santen Pharmaceutical Co., Ltd. | New cyclic compound having pyrimidinylalkylthio group |
TW201414495A (en) * | 2005-04-04 | 2014-04-16 | Tibotec Pharm Ltd | Prevention of HIV-infection |
CA2607021C (en) | 2005-05-05 | 2013-10-29 | Ardea Biosciences, Inc. | Diaryl-purines, -azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv |
CA2609716C (en) * | 2005-05-26 | 2014-10-14 | Tibotec Pharmaceuticals Ltd. | Process for preparing 4-[(1,6-dihydro-6-oxo-2-pyrimidinyl)amino]benzonitrile |
CN101208089A (en) | 2005-06-03 | 2008-06-25 | 泽农医药公司 | Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
EP1904457B1 (en) | 2005-06-08 | 2017-09-06 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
JP5247470B2 (en) | 2006-01-19 | 2013-07-24 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
PL1981506T6 (en) | 2006-01-20 | 2021-07-12 | Janssen Sciences Ireland Uc | Long term treatment of hiv- infection with tcm278 |
EP2004641B1 (en) | 2006-03-30 | 2010-09-29 | Tibotec Pharmaceuticals | Hiv inhibiting 5-(hydroxymethylene and aminomethylene) substituted pyrimidines |
RU2480464C2 (en) | 2006-03-30 | 2013-04-27 | Тиботек Фармасьютикалз Лтд. | Hiv-inhibiting 5-amido-substituted pyrimidines |
AU2014200819B2 (en) * | 2006-06-23 | 2016-05-26 | Janssen Sciences Ireland Uc | Aqueous suspensions of TMC278 |
CA2654115C (en) * | 2006-06-23 | 2015-12-22 | Tibotec Pharmaceuticals Ltd. | Aqueous suspensions of tmc278 |
AU2016219555B2 (en) * | 2006-06-23 | 2017-08-10 | Janssen Sciences Ireland Uc | Aqueous suspensions of TMC278 |
CA2668997C (en) | 2006-11-09 | 2012-10-09 | Ardea Biosciences, Inc. | 4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors |
EP3012249A1 (en) | 2006-12-08 | 2016-04-27 | Novartis AG | Compounds and composition as protein kinase inhibitors |
RU2469032C2 (en) * | 2006-12-13 | 2012-12-10 | Ф.Хоффманн-Ля Рош Аг | 2-(piperidin-4-yl)-4-phenoxy- or phenylaminopyrimidine derivatives as non nucleoside reverse transcriptase inhibitors |
BRPI0722079B8 (en) | 2006-12-29 | 2021-05-25 | Janssen R & D Ireland | 5,6-substituted hiv-inhibiting pyrimidines and pharmaceutical composition comprising them |
JP5185283B2 (en) | 2006-12-29 | 2013-04-17 | テイボテク・フアーマシユーチカルズ | HIV inhibitory 6-substituted pyrimidines |
JP2010518014A (en) * | 2007-01-31 | 2010-05-27 | バーテックス ファーマシューティカルズ インコーポレイテッド | 2-Aminopyridine derivatives useful as kinase inhibitors |
CL2008000746A1 (en) * | 2007-03-14 | 2008-09-22 | Tibotec Pharm Ltd | PHARMACEUTICAL COMPOSITION IN SOLUTION INCLUDING TMC278 AND A WATER SOLUBLE POLYMER; PREPARATION PROCESS OF SUCH COMPOSITION; AND USE OF A POWDER UNDERSTANDING TMC278 TO TREAT AIDS. |
EA016679B1 (en) * | 2007-04-18 | 2012-06-29 | Пфайзер Продактс Инк. | Sulfonyl amide derivatives for the treatment of abnormal cell growth |
EP2155692B1 (en) | 2007-05-30 | 2015-06-17 | F. Hoffmann-La Roche AG | Non-nucleoside reverse transcriptase inhibitors |
KR101294731B1 (en) * | 2007-06-04 | 2013-08-16 | 삼성디스플레이 주식회사 | Array substrate, display panel having the array substrate and method of manufacturing the array substrate |
EP2175857B1 (en) | 2007-07-12 | 2013-09-11 | Janssen R&D Ireland | Crystalline form of (e) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
CN101407476B (en) * | 2007-10-12 | 2012-07-18 | 中国人民解放军军事医学科学院毒物药物研究所 | M-bis(arene) polysubstituted aniline compound as non-nucleoside HIV reverse transcriptase inhibitor, and preparation and use thereof |
TWI415840B (en) | 2007-11-27 | 2013-11-21 | Ardea Biosciences Inc | Novel compounds and compositions and methods of use |
EP2220091B1 (en) | 2007-12-14 | 2012-07-25 | Ardea Biosciences, Inc. | Reverse transcriptase inhibitors |
US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
ES2711249T3 (en) | 2008-06-27 | 2019-04-30 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US8569337B2 (en) | 2008-07-23 | 2013-10-29 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
WO2010011768A1 (en) | 2008-07-23 | 2010-01-28 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
NZ590784A (en) | 2008-07-23 | 2012-12-21 | Vertex Pharma | Pyrazolopyridine kinase inhibitors |
MX2011001319A (en) * | 2008-08-06 | 2011-04-05 | Vertex Pharma | Aminopyridine kinase inhibitors. |
EP2351739B1 (en) | 2008-10-09 | 2013-07-31 | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China | 2-(4-substituted phenylamino) polysubstituted pyridine compounds as the inhibitors of non-nucleoside hiv reverse transcriptase, praparation methods and uses thereof |
CN101717364B (en) * | 2008-10-09 | 2014-08-13 | 中国人民解放军军事医学科学院毒物药物研究所 | Paradoximes as HIV reverse transcriptase inhibitor as well as preparation method and purpose thereof |
EP2181991A1 (en) | 2008-10-28 | 2010-05-05 | LEK Pharmaceuticals D.D. | Novel salts of sunitinib |
EP2186809A1 (en) | 2008-11-13 | 2010-05-19 | LEK Pharmaceuticals D.D. | New crystal form of sunitinib malate |
EP2381961B1 (en) | 2008-12-24 | 2016-09-14 | Janssen Sciences Ireland UC | Implantable devices for treating hiv |
KR101705158B1 (en) | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Egfr inhibitors and methods of treating diseases |
JP5627675B2 (en) | 2009-05-06 | 2014-11-19 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Pyrazolopyridine |
CA2787315A1 (en) | 2010-01-27 | 2011-08-04 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridine kinase inhibitors |
AU2011209649A1 (en) | 2010-01-27 | 2012-08-09 | Vertex Pharmaceuticals Incorporated | Pyrazolopyrazine kinase inhibitors |
DK3494972T3 (en) | 2010-01-27 | 2024-01-29 | Viiv Healthcare Co | Combinations of dolutegravir and lamivudine for the treatment of HIV infection |
AU2011209651A1 (en) | 2010-01-27 | 2012-08-09 | Vertex Pharmaceuticals Incorporated | Pyrazolopyrimidine kinase inhibitors |
WO2011103457A1 (en) | 2010-02-18 | 2011-08-25 | Concert Pharmaceuticals Inc. | Pyrimidine derivatives |
US8367315B2 (en) * | 2010-03-05 | 2013-02-05 | Adan Rios | Inactivation of reverse transcriptases by azido-diarylpyrimidines |
KR20130099040A (en) | 2010-08-10 | 2013-09-05 | 셀진 아빌로믹스 리서치, 인코포레이티드 | Besylate salt of a btk inhibitor |
ES2635713T3 (en) | 2010-11-01 | 2017-10-04 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
NZ609957A (en) | 2010-11-01 | 2015-08-28 | Celgene Avilomics Res Inc | Heterocyclic compounds and uses thereof |
WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
JP5957003B2 (en) | 2010-11-10 | 2016-07-27 | セルジーン アヴィロミクス リサーチ, インコーポレイテッド | Mutant selective EGFR inhibitor and use thereof |
TWI556840B (en) | 2010-11-19 | 2016-11-11 | 吉李德科學股份有限公司 | Therapeutic compositions |
WO2012125993A1 (en) | 2011-03-17 | 2012-09-20 | Teva Pharmaceutical Industries Ltd. | Solid state forms of rilpivirine base, and rilipivirine salts |
US9126949B2 (en) | 2011-04-25 | 2015-09-08 | Hetero Research Foundation | Process for rilpivirine |
PT2750677T (en) | 2011-08-30 | 2017-07-03 | Chdi Foundation Inc | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
ES2680146T3 (en) * | 2011-09-16 | 2018-09-04 | Hetero Research Foundation | Rilpivirine Hydrochloride |
JP2014532658A (en) | 2011-10-28 | 2014-12-08 | セルジーン アヴィロミクス リサーチ, インコーポレイテッド | Methods for treating Breton tyrosine kinase diseases or disorders |
EP2628732A1 (en) | 2012-02-20 | 2013-08-21 | Sandoz AG | Novel crystalline form of rilpivirine hydrochloride |
WO2013087794A1 (en) | 2011-12-14 | 2013-06-20 | Sandoz Ag | Polymorph of rilpivirine hydrochloride and its use as antiviral |
EP2604593A1 (en) | 2011-12-14 | 2013-06-19 | Sandoz AG | Polymorph of Rilpivirine hydrochloride and its use as antiviral |
SG10201700799WA (en) | 2012-03-15 | 2017-02-27 | Celgene Avilomics Res Inc | Salts of an epidermal growth factor receptor kinase inhibitor |
ES2880109T3 (en) | 2012-03-15 | 2021-11-23 | Celgene Car Llc | Solid forms of an epidermal growth factor receptor kinase inhibitor |
WO2013153162A1 (en) | 2012-04-11 | 2013-10-17 | Sandoz Ag | Polymorph of rilpivirine hydrochloride |
WO2013153161A2 (en) | 2012-04-11 | 2013-10-17 | Sandoz Ag | Novel polymorph of rilpivirine hydrochloride |
WO2013179105A1 (en) * | 2012-06-01 | 2013-12-05 | Laurus Labs Private Limited | Improved process for preparation of rilpivirine and pharmaceutically acceptable salts thereof |
US9139535B2 (en) * | 2012-07-12 | 2015-09-22 | Hetero Research Foundation | Process for rilpivirine using novel intermediate |
WO2014072419A1 (en) | 2012-11-08 | 2014-05-15 | Universiteit Antwerpen | Novel anti-hiv compounds |
EP2935226A4 (en) | 2012-12-21 | 2016-11-02 | Celgene Avilomics Res Inc | Heteroaryl compounds and uses thereof |
WO2014124230A2 (en) | 2013-02-08 | 2014-08-14 | Celgene Avilomics Research, Inc. | Erk inhibitors and uses thereof |
US9914709B2 (en) | 2013-06-21 | 2018-03-13 | Yale University | Compositions and methods of treating HIV-1 infections using same |
US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
UA120856C2 (en) * | 2014-07-17 | 2020-02-25 | Кхді Фаундейшн, Інк. | Methods and compositions for treating hiv-related disorders |
EP3179858B1 (en) | 2014-08-13 | 2019-05-15 | Celgene Car Llc | Forms and compositions of an erk inhibitor |
CN106999425A (en) | 2014-09-26 | 2017-08-01 | 葛兰素史克知识产权第二有限公司 | Depot drug product composition |
CZ201532A3 (en) | 2015-01-21 | 2015-02-25 | Zentiva, K.S. | Process for preparing extremely pure rilpivirine and salt thereof |
CN104926829A (en) * | 2015-06-08 | 2015-09-23 | 山东大学 | Thieno miazines derivatives and preparation method and application thereof |
PT3607939T (en) | 2015-06-30 | 2022-09-12 | Gilead Sciences Inc | Pharmaceutical formulations |
CZ2015579A3 (en) | 2015-08-27 | 2017-03-08 | Zentiva, K.S. | The crystalline form of A rilpivirine adipate and method of its preparation |
CN106187916B (en) * | 2016-07-04 | 2018-08-21 | 宜昌人福药业有限责任公司 | A method of effectively removing rilpivirine isomers |
RS65159B1 (en) | 2016-10-24 | 2024-02-29 | Janssen Sciences Ireland Unlimited Co | Dispersible compositions |
CN106749203B (en) * | 2016-11-28 | 2020-04-10 | 洛阳聚慧医药科技有限公司 | Pyrimidine heterocyclic compound, pyrimidine heterocyclic compound salt, preparation method and application |
CN106588696B (en) * | 2016-12-08 | 2018-12-25 | 西北师范大学 | A kind of preparation method of trans- 'alpha ', ' bela '-unsaturated nitrile class compound |
CN106905244B (en) * | 2017-02-27 | 2019-08-16 | 武汉工程大学 | Diaryl pyrimidine-diketone acid heterozygous HIV-1 inhibitor and preparation method thereof |
CA3113234A1 (en) | 2018-09-18 | 2020-03-26 | Nikang Therapeutics, Inc. | Tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors |
CN109293581B (en) * | 2018-09-21 | 2020-03-27 | 宜昌人福药业有限责任公司 | Method for preparing rilpivirine hydrochloride isomer Z and impurity X and application of impurity X as pesticide in agriculture |
WO2020084142A1 (en) | 2018-10-25 | 2020-04-30 | Minakem | Process for the preparation of rilpivirine |
US20210000823A1 (en) * | 2019-07-03 | 2021-01-07 | Janssen Sciences Ireland Unlimited Company | Methods of treating hiv |
CN110526873B (en) * | 2019-08-15 | 2022-09-16 | 复旦大学 | Cyanovinyl substituted benzodiarylpyrimidine compound and preparation method and application thereof |
US11166952B2 (en) | 2019-11-29 | 2021-11-09 | Aptorum Therapeutics Limited | Composition including rilpivirine and method for treating tumors or cancer |
CN111004215B (en) * | 2019-12-22 | 2022-08-09 | 华北理工大学 | 2, 4-substituted pyrimidine derivatives, preparation method thereof and application thereof in preparing antitumor drugs |
CN111217833B (en) * | 2020-02-21 | 2021-03-16 | 山东大学 | Thieno [2,3-d ] pyrimidine HIV-1 non-nucleoside reverse transcriptase inhibitor and preparation method and application thereof |
AU2021302678A1 (en) * | 2020-06-30 | 2023-02-09 | University Of South Australia | New therapeutic use of Rilpivirine |
CN112010810B (en) * | 2020-09-09 | 2024-01-30 | 瑞阳制药股份有限公司 | Method for preparing high-purity rilpivirine intermediate by one-pot method |
CN112028836B (en) * | 2020-09-09 | 2021-12-07 | 山东大学 | Diarylpyrimidine derivative containing six-membered nitrogen heterocycle and preparation method and application thereof |
WO2022079739A1 (en) | 2020-10-14 | 2022-04-21 | Cipla Limited | Fixed dose compositions of cabotegravir and rilpivirine |
TW202233192A (en) | 2020-11-17 | 2022-09-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | Treatment or prevention of hiv infection |
CN112546969B (en) * | 2020-12-07 | 2022-12-23 | 安徽贝克制药股份有限公司 | Catalytic hydrogenation continuous production device and preparation method of ritonavir intermediate |
CN112778214A (en) * | 2021-01-13 | 2021-05-11 | 安徽贝克联合制药有限公司 | Intermediate for synthesizing rilpivirine, synthesis method thereof and rilpivirine synthesis method |
CN113105394A (en) * | 2021-03-08 | 2021-07-13 | 复旦大学 | Biphenyl diaryl pyrimidine derivative containing aromatic heterocyclic structure and preparation method and application thereof |
CN113461666A (en) * | 2021-05-06 | 2021-10-01 | 复旦大学 | Biphenyl diaryl methyl pyrimidine derivative containing aromatic heterocyclic structure and preparation method thereof |
CN113845515A (en) * | 2021-09-03 | 2021-12-28 | 复旦大学 | Aromatic heterocyclic structure-containing dimethyl biphenyl diaryl pyrimidine derivative and preparation method and application thereof |
CA3234763A1 (en) | 2021-11-17 | 2023-05-25 | Janssen Sciences Ireland Unlimited Company | Dissolution test |
TW202406551A (en) | 2022-04-22 | 2024-02-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | Freeze dried compositions |
WO2023203258A1 (en) | 2022-04-22 | 2023-10-26 | Janssen Sciences Ireland Unlimited Company | Liquid compositions |
WO2023222754A1 (en) | 2022-05-17 | 2023-11-23 | Janssen Sciences Ireland Unlimited Company | Rilpivirine for use in the treatment or prevention of hiv infection |
WO2023222755A1 (en) | 2022-05-17 | 2023-11-23 | Janssen Sciences Ireland Unlimited Company | Treatment or prevention of hiv infection |
CN115490642A (en) * | 2022-09-21 | 2022-12-20 | 山东大学 | Diaryl pyrimidine compound containing ether bond and preparation method and application thereof |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
US3953398A (en) * | 1970-07-20 | 1976-04-27 | The Goodyear Tire & Rubber Company | Age resistant polymeric compositions |
JPS63159316A (en) * | 1977-11-28 | 1988-07-02 | アルキユサル インコーポレーテツド ピーテイワイ リミテツド | Antiinflammatory composition containing neutral copper bonded body |
EP0002341B1 (en) * | 1977-11-28 | 1982-01-20 | Barry Boettcher | Complexes of bivalent copper, methods of preparation thereof and compositions containing said complexes |
JPS5879920A (en) * | 1981-11-09 | 1983-05-13 | Kanegafuchi Chem Ind Co Ltd | Inhibitor against blood platelet aggregation |
GB9012592D0 (en) | 1990-06-06 | 1990-07-25 | Smithkline Beecham Intercredit | Compounds |
US5318780A (en) * | 1991-10-30 | 1994-06-07 | Mediventures Inc. | Medical uses of in situ formed gels |
US5691364A (en) | 1995-03-10 | 1997-11-25 | Berlex Laboratories, Inc. | Benzamidine derivatives and their use as anti-coagulants |
GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
NZ322907A (en) | 1995-11-23 | 1998-12-23 | Janssen Pharmaceutica Nv | Solid mixtures of cyclodextrins prepared via melt-extrusion |
TW429256B (en) | 1995-12-27 | 2001-04-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives |
GB9705361D0 (en) | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
JP3990808B2 (en) * | 1998-03-26 | 2007-10-17 | Tdk株式会社 | Method for producing electrode for non-aqueous electrolyte battery |
ES2361146T3 (en) * | 1998-03-27 | 2011-06-14 | Janssen Pharmaceutica Nv | DERIVATIVES OF HIV INHIBITATORY PYRAMIDINE. |
EP0945447A1 (en) * | 1998-03-27 | 1999-09-29 | Janssen Pharmaceutica N.V. | Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections |
SK287996B6 (en) | 1998-03-27 | 2012-09-03 | Janssen Pharmaceutica N. V. | Pyrimide compound, pharmaceutical composition the compound is comprised, method for preparation thereof, combination and product containing the composition and use of the pyrimide compound |
JP2000035628A (en) * | 1998-07-16 | 2000-02-02 | Konica Corp | Silver halide photographic sensitive material |
DE69933680T2 (en) * | 1998-08-29 | 2007-08-23 | Astrazeneca Ab | PYRIMIDINE COMPOUNDS |
HU230394B1 (en) | 1998-11-10 | 2016-04-28 | Janssen Pharmaceutica N.V. | Hiv replication inhibiting pyrimidines |
ES2184705T3 (en) | 1999-03-09 | 2003-04-16 | Upjohn Co | 4-OXO-4,7-DIHIDRO-TIENO (2,3-B) PIRIDINA-5-CARBOXAMIDS AS ANTIVIRAL AGENTS. |
IL144910A0 (en) | 1999-04-15 | 2002-06-30 | Bristol Myers Squibb Co | Cyclic compounds and pharmaceutical compositions containing the same |
GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
DE19945982A1 (en) | 1999-09-24 | 2001-03-29 | Knoll Ag | Velocity-determined particles |
AU775360B2 (en) * | 1999-09-24 | 2004-07-29 | Janssen Pharmaceutica N.V. | Antiviral compositions |
CA2400447C (en) * | 2000-02-17 | 2008-04-22 | Amgen Inc. | Kinase inhibitors |
GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
AU782948B2 (en) | 2000-05-08 | 2005-09-15 | Janssen Pharmaceutica N.V. | Prodrugs of HIV replication inhibiting pyrimidines |
EP1282606B1 (en) | 2000-05-08 | 2015-04-22 | Janssen Pharmaceutica NV | Hiv replication inhibiting pyrimidines and triazines |
US6596729B2 (en) * | 2000-07-20 | 2003-07-22 | Bristol-Myers Squibb Company | Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors |
PL364658A1 (en) | 2001-03-02 | 2004-12-13 | Smithkline Beecham Corporation | Benzophenones as inhibitors of reverse transcriptase |
MXPA03008888A (en) * | 2001-03-29 | 2005-03-07 | Vertex Pharma | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases. |
MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
US7638522B2 (en) | 2001-08-13 | 2009-12-29 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile |
US8101629B2 (en) * | 2001-08-13 | 2012-01-24 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
JO3429B1 (en) * | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | Hiv inhibiting pyrimidines derivatives |
CA2457526A1 (en) * | 2001-08-29 | 2003-03-13 | Umd, Inc. | Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy |
TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
US20060034797A1 (en) * | 2002-05-03 | 2006-02-16 | Arien Albertina M E | Polymeric micromulsions |
CN102702111B (en) | 2002-08-09 | 2014-12-17 | 詹森药业有限公司 | Processes for the preparation of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile |
AU2002350719A1 (en) * | 2002-11-29 | 2004-06-23 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
MXPA05008364A (en) * | 2003-02-07 | 2005-11-04 | Janssen Pharmaceutica Nv | Pyrimidine derivatives for the prevention of hiv infection. |
US9226970B2 (en) * | 2010-02-22 | 2016-01-05 | Nektar Therapeutics | Oligomer modified diaromatic substituted compounds |
-
2002
- 2002-07-16 JO JOP/2002/0074A patent/JO3429B1/en active
- 2002-08-09 EA EA200400304A patent/EA006656B1/en active IP Right Maintenance
- 2002-08-09 ES ES10178189T patent/ES2799408T3/en not_active Expired - Lifetime
- 2002-08-09 CN CN200910145401.5A patent/CN101816658B/en not_active Expired - Lifetime
- 2002-08-09 PL PL368270A patent/PL216398B1/en unknown
- 2002-08-09 SI SI200231101T patent/SI3808743T1/en unknown
- 2002-08-09 DK DK20165399.5T patent/DK3808743T3/en active
- 2002-08-09 AP APAP/P/2004/002993A patent/AP1610A/en active
- 2002-08-09 US US10/485,636 patent/US7125879B2/en active Active
- 2002-08-09 KR KR1020077022611A patent/KR100969273B1/en active Protection Beyond IP Right Term
- 2002-08-09 JP JP2003521229A patent/JP2005507380A/en not_active Withdrawn
- 2002-08-09 IL IL16032802A patent/IL160328A0/en active IP Right Grant
- 2002-08-09 BR BR0211909-9 patent/BRPI0211909B8/en active IP Right Grant
- 2002-08-09 OA OA1200400047A patent/OA12652A/en unknown
- 2002-08-09 BR BR122015032641-9A patent/BR122015032641B1/en not_active IP Right Cessation
- 2002-08-09 BR BR122015023612A patent/BR122015023612B8/en not_active IP Right Cessation
- 2002-08-09 PT PT02764839T patent/PT1419152E/en unknown
- 2002-08-09 CA CA002452217A patent/CA2452217C/en not_active Expired - Lifetime
- 2002-08-09 ES ES02764839T patent/ES2368996T3/en not_active Expired - Lifetime
- 2002-08-09 KR KR1020047000372A patent/KR100817453B1/en active IP Right Review Request
- 2002-08-09 EP EP02764839A patent/EP1419152B1/en not_active Expired - Lifetime
- 2002-08-09 HU HU0401346A patent/HU230192B1/en active Protection Beyond IP Right Term
- 2002-08-09 EP EP20165399.5A patent/EP3808743B1/en not_active Expired - Lifetime
- 2002-08-09 EP EP10178189.6A patent/EP2298761B1/en not_active Expired - Lifetime
- 2002-08-09 SI SI200230963T patent/SI1419152T1/en unknown
- 2002-08-09 AU AU2002329238A patent/AU2002329238C1/en active Active
- 2002-08-09 CN CNB028159209A patent/CN100509801C/en not_active Expired - Lifetime
- 2002-08-09 ES ES20165399T patent/ES2923581T3/en not_active Expired - Lifetime
- 2002-08-09 DK DK02764839.3T patent/DK1419152T3/en active
- 2002-08-09 HR HRP20192051AA patent/HRP20192051B1/en not_active IP Right Cessation
- 2002-08-09 AT AT02764839T patent/ATE517891T1/en active
- 2002-08-09 MY MYPI20071005A patent/MY189572A/en unknown
- 2002-08-09 WO PCT/EP2002/008953 patent/WO2003016306A1/en active Application Filing
- 2002-08-09 HU HU1900370A patent/HU231274B1/en active Protection Beyond IP Right Term
- 2002-08-09 PL PL402388A patent/PL402388A1/en unknown
- 2002-08-09 NZ NZ530951A patent/NZ530951A/en not_active IP Right Cessation
- 2002-08-09 LT LTEP20165399.5T patent/LT3808743T/en unknown
- 2002-08-09 MX MXPA04001401A patent/MXPA04001401A/en active IP Right Grant
- 2002-08-10 EG EG2002080892A patent/EG24684A/en active
- 2002-08-12 AR ARP020103034A patent/AR036387A1/en active IP Right Grant
- 2002-08-12 PA PA20028552901A patent/PA8552901A1/en unknown
- 2002-09-08 UA UA2004031903A patent/UA78221C2/en unknown
-
2004
- 2004-01-29 HR HRP20040096AA patent/HRP20040096B1/en not_active IP Right Cessation
- 2004-02-11 IL IL160328A patent/IL160328A/en active Protection Beyond IP Right Term
- 2004-02-12 NO NO20040633A patent/NO327639B1/en not_active IP Right Cessation
- 2004-02-12 ZA ZA2004/01159A patent/ZA200401159B/en unknown
-
2005
- 2005-04-01 HK HK05102760.9A patent/HK1070066A1/en not_active IP Right Cessation
-
2006
- 2006-06-26 US US11/474,855 patent/US8080551B2/en not_active Expired - Fee Related
-
2008
- 2008-09-02 NO NO20083770A patent/NO337142B1/en not_active IP Right Cessation
-
2009
- 2009-11-12 JP JP2009259107A patent/JP5247661B2/en not_active Expired - Lifetime
-
2010
- 2010-12-21 HK HK10111939.9A patent/HK1145449A1/en not_active IP Right Cessation
-
2011
- 2011-06-16 JP JP2011134088A patent/JP4838396B2/en not_active Expired - Lifetime
- 2011-06-17 JP JP2011135468A patent/JP5539927B2/en not_active Expired - Lifetime
- 2011-09-30 US US13/249,796 patent/US20120076835A1/en not_active Abandoned
- 2011-10-26 CY CY20111101014T patent/CY1112331T1/en unknown
-
2012
- 2012-03-23 HR HRP20120265A patent/HRP20120265B1/en not_active IP Right Cessation
- 2012-05-08 BE BE2012C020C patent/BE2012C020I2/nl unknown
- 2012-05-16 LU LU92001C patent/LU92001I2/en unknown
- 2012-05-18 CY CY2012012C patent/CY2012012I1/en unknown
- 2012-05-22 FR FR12C0035C patent/FR12C0035I2/en active Active
- 2012-05-23 NO NO2012010C patent/NO2012010I2/en unknown
- 2012-05-24 LU LU92008C patent/LU92008I2/en unknown
- 2012-05-24 BE BE2012C022C patent/BE2012C022I2/nl unknown
- 2012-05-25 CY CY2012013C patent/CY2012013I1/en unknown
- 2012-05-25 DE DE201212000038 patent/DE122012000038I1/en active Pending
- 2012-05-25 FR FR12C0036C patent/FR12C0036I2/en active Active
-
2014
- 2014-08-05 US US14/451,761 patent/US9580392B2/en not_active Expired - Lifetime
-
2015
- 2015-10-20 HU HUS1500051C patent/HUS1500051I1/en unknown
-
2016
- 2016-02-03 HU HUS1500055C patent/HUS1500055I1/en unknown
-
2017
- 2017-01-16 US US15/406,918 patent/US20170121292A1/en not_active Abandoned
- 2017-07-20 US US15/655,570 patent/US9981919B2/en not_active Expired - Lifetime
-
2018
- 2018-04-26 US US15/963,352 patent/US10370340B2/en not_active Expired - Fee Related
-
2019
- 2019-07-02 US US16/460,898 patent/US10611732B2/en not_active Expired - Fee Related
-
2022
- 2022-07-27 FR FR22C1036C patent/FR22C1036I1/en active Active
- 2022-07-28 BE BE2022C531C patent/BE2022C531I2/nl unknown
- 2022-08-02 HU HUS2200038C patent/HUS2200038I1/en unknown
- 2022-08-02 LT LTPA2022515C patent/LTC3808743I2/lt unknown